Skip to Main Content

News & Views

Press Releases

Volastra Therapeutics Named One of Fierce Biotech’s “Fierce 15” Companies of 2022

September 12, 2022

NEW YORK, September 12, 2022 – Volastra Therapeutics, an oncology company focused on exploiting chromosomal...

Volastra Therapeutics to Present Preclinical Data from KIF18A Inhibitor Program Targeting Chromosomally Unstable Tumors at FASEB Aneuploidy Conference

September 9, 2022

Treatment with KIF18A inhibitor led to substantial, dose-dependent inhibition of tumor growth in multiple tumor...

Volastra Therapeutics Announces Participation in 2022 Guggenheim Synthetic Lethality Day

NEW YORK, May 12, 2022 – Volastra Therapeutics, an oncology company focused on exploiting chromosomal...

Our Perspectives

A closer look at Volastra’s lead program: KIF18A inhibitor

September 29, 2022

By Christina Eng, Ph.D., VP, Head of Biology Earlier this month at the FASEB Consequences...

Getting to Know Scott Drutman, M.D., Ph.D., SVP, Head of Translational Science

November 8, 2021

Welcome to Scott Drutman, M.D., Ph.D., who recently joined Volastra as Senior Vice President, Head...

Charting Volastra’s R&D path

October 4, 2021

By Michael Arensman, Aaron Phillips and Hyeseok Shim Every medicine starts with a discovery. But...

In The News

On heels of landmark approval, Bristol Myers Squibb embarks on billion-dollar oncology deal with metastatic cancer startup

Bristol Myers lands $1.1B biobucks oncology pact with Volastra, a biotech with phones ‘ringing off the hook’

Researchers see a ‘tractable approach’ to taming cancer metastasis

Presentations

2022 Guggenheim Synthetic Lethality Day

Contact Us

Volastra
1361 Amsterdam Ave Suite 520
New York, NY 10027
Phone: (646) 344-1248
contactus@volastratx.com

Media Contact
Lisa Qu
Ten Bridge Communications
(678) 662-9166
LQu@tenbridgecommunications.com